Patrick Campbell

A review of data from the prospective SmartCare-CAD trial details the primary drivers of nonparticipation in telerehabilitation programs among patients with cardiovascular conditions.

A retrospective review with nearly a year of follow-up indicates nearly 40% of newly diagnosed diabetes at COVID-19 admission regressed to prediabetes or normoglycemia at follow-up, suggesting stress hyperglycemia induced by COVID-19-related acute stress could be driving rates of diagnosis.

The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.

A meta-analysis of studies assessing presence of pathological eating behaviors and risk of diabetic retinopathy was associated with a more than 3-fold increase in risk of retinopathy.

Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.

New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.

A new study indicates a novel, 2-step deep learning algorithm developed using echocardiogram videos was able to identify left ventricular hypertrophy and the cause with greater accuracy than trained clinicians.

Announced on Feb. 24, the approval indicates the SGLT2 inhibitor for reducing risk of CV death and hospitalizations for heart failure in adults with heart failure and is supported by data from the EMPEROR-Preserved trial.

An analysis of data from more than 16,000 patients demonstrates the added benefit interventions delivered in primary care settings can have on physical activity levels among adult patients.

An analysis comparing 15-year outcomes following Ross procedure and biological or mechanical aortic valve replacement provides insight into the risk of mortality and other adverse outcomes associated with each procedure.

Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.

An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.

Announced by Abbott on Feb. 21, the expanded indication for the CardioMEMS HF System now includes patients with NYHA Class II heart failure and those with worsening heart failure, which expands the potential patient population by 1.2 million additional patients.

Announced on Feb. 18, the t:connect mobile app, which pairs with the t:slim X2 insulin pump, is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems, according to Tandem Diabetes Care.

A retrospective cohort study suggests users of DOACs were at a 16% lower risk of developing macrovascular complications, a 21% lower risk of microvascular complications, and a 22% lower risk of mortality compared with warfarin users among a population of patients with diabetes and atrial fibrillation.

A single-center retrospective analysis of data from an endocrinology clinic in Turkey provides insight into an apparent increase in diagnoses of idiopathic central precocious puberty.

A new study in JAMA Network Open provides an overview of the cost-effectiveness of icosapent ethyl at multiple prices in high-risk patients with hypertriglyceridemia despite statin therapy.

An economic evaluation using a microsimulation model comparing Roux-en-Y gastric bypass, sleeve gastrectomy, and medical therapy for severe obesity in patients with type 2 diabetes suggests gastric bypass was the most cost-effective approach.

A systematic review and meta-analysis suggest approximately 20% of girls with type 2 diabetes also had polycystic ovary syndrome.

Data from a national research database in Taiwan provides insight into the apparent reductions in risk associated with DOAC use compared to warfarin in patients with atrial fibrillation and diabetes.

Data from Medicare beneficiaries provide insight into the risk of stroke associated with a diagnosis of COVID-19 among older adults, which results suggest peaks within the first 3 days of diagnosis.

A retrospective analysis of 10 years of stroke admissions suggests pediatric stroke patients with LVO who did not undergo thrombectomy were at 6 times greater risk of moderate to severe disability or death than those who underwent thrombectomy.

Announced on February 11, the approval for Eversense E3 continuous glucose monitoring system allows access to a CGM system with 6 months of longevity and is expected to be available beginning in the second quarter of 2022.

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.

A meta-analysis presented at ISC 2022 suggests the risk of in-hospital mortality for stroke-related admissions was 42% greater among patients hospitalized during the pandemic compared to prepandemic.

On the first day of International Stroke Conference 2022, the AHA released a scientific statement outlining strategies to optimize in-hospital stroke care.

Using a pair of composite scores for measuring sleep health, new research from USF demonstrates the impact poor sleep health can have on risk of cardiovascular disease among adults in midlife.

Data from the SURPASS-5 trial demonstrate the safety and efficacy of multiple tirzepatide doses as an add-on therapy to titrated insulin glargine for glycemic control and weight loss in patients with type 2 diabetes.

Data from the PATH-BP study suggests patients receiving daily acetaminophen experienced significant increases in systolic and diastolic blood pressure after just 2 weeks of receiving the medication.

Analysis of the UK Biobank cohort suggests presence of gestational diabetes was associated with a 33% increase in risk of CAD, 67% increase in risk of myocardial infarction, 69% increase in risk of stroke, and 42% increase in risk heart failure.